Q3 revenue hit $24.40 billion, up 39% from a year ago. China's reimbursement listing for Mounjaro helped drive international demand.
Recap by typeshit. Full story at 24/7 Wall St..
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
In MIRA's early mouse study, SKNY-1 cut weight without lowering food intake. The company says lean mass held up better than with semaglutide.
A short Instagram clip from @realdrbae on side effects he links to the GLOW blend. These are his claims, and the clip itself gives few details.
Loading…